Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors

P Monnet; F Herms; M Djermane; S Dalac; O Dereure; B Dréno; M Beylot-Barry; L Mortier; N Basset-Seguin

doi:10.1111/bjd.20808

Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors

Br J Dermatol. 2022 Mar;186(3):579-581. doi: 10.1111/bjd.20808. Epub 2021 Nov 24.

Authors

P Monnet¹, F Herms^{1

2}, M Djermane^{1

2}, S Dalac^{2

3}, O Dereure^{2

4}, B Dréno^{2

5}, M Beylot-Barry^{2

6}, L Mortier^{2

7}, N Basset-Seguin^{1

2}

Affiliations

¹ Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France.
² CARADERM (Cancers RAres en DERMatologie), Lille, France.
³ Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France.
⁴ Dermatology Department, Montpellier University Hospital, Montpellier, France.
⁵ Dermatology Department, Nantes University Hospital, Nantes, France.
⁶ Dermatology Department, Saint-André Hospital, Bordeaux, France.
⁷ Dermatology Department, Lille University Hospital, Lille, France.

PMID: 34817864
DOI: 10.1111/bjd.20808

No abstract available

Publication types

Letter

MeSH terms

Anilides / pharmacology
Anilides / therapeutic use
Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Carcinoma, Basal Cell* / pathology
Hedgehog Proteins / metabolism
Humans
Skin Neoplasms* / pathology

Substances

Anilides
Antineoplastic Agents
Hedgehog Proteins